leisure time -WSS

leisure time

author：explore 2025-10-01 00:16:57 - browse：93596

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： CMS should re

WSS

Pregnancy discrimination could be enabled by AI

Sanofi strikes deal with Novavax, boosting the vaccine maker

Use wet bulb globe temperature, not heat index, to protect workers

Patients' immediate access to test results puts radiologists in a bind

Spinal cord stimulation reduces pain in amputees, study finds

After sickle

leisure time

leisure time

The contrarian view of Viking Therapeutics

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Elevance, private equity launch primary care company

Medical leaders decry Supreme Court decision on affirmative action

Readout LOUD podcast: What to know about H5N1 bird flu

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why sickle cell disease is getting the first CRISPR treatment

Cancer drug shortages should be causing more outrage

In diabetes hearing, Sanders takes on a new foe: food makers

Supreme Court strikes down use of affirmative action

Pregnancy discrimination could be enabled by AI

entertainment

Leukemia patients are helped by Syndax's new type of therapy

Roche to buy Carmot Therapeutics, developer of obesity drugs

First recipient of genetically engineered pig kidney has died

The woman behind the Dana Farber

FDA approves world's first CRISPR

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

leisure time

explore

hotspot

knowledge